NASDAQ:KZR - Kezar Life Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.09 -0.30 (-1.47 %) (As of 05/20/2019 12:20 PM ET)Previous Close$20.39Today's Range$20.09 - $20.0952-Week Range$14.77 - $36.33Volume100 shsAverage Volume55,158 shsMarket Capitalization$384.12 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California. Receive KZR News and Ratings via Email Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZR Previous Symbol CUSIPN/A CIKN/A Webwww.kezarlifesciences.com Phone650-822-5600Debt Debt-to-Equity Ratio0.06 Current Ratio21.81 Quick Ratio21.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book3.76Profitability EPS (Most Recent Fiscal Year)($2.26) Net Income$-23,170,000.00 Net MarginsN/A Return on Equity-23.28% Return on Assets-21.84%Miscellaneous Employees24 Outstanding Shares19,120,000Market Cap$384.12 million Next Earnings Date8/8/2019 (Estimated) OptionableNot Optionable Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions What is Kezar Life Sciences' stock symbol? Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR." How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences Inc (NASDAQ:KZR) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. View Kezar Life Sciences' Earnings History. When is Kezar Life Sciences' next earnings date? Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Kezar Life Sciences. What price target have analysts set for KZR? 4 Wall Street analysts have issued 1-year target prices for Kezar Life Sciences' shares. Their predictions range from $23.00 to $30.00. On average, they anticipate Kezar Life Sciences' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences. What is the consensus analysts' recommendation for Kezar Life Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences. Has Kezar Life Sciences been receiving favorable news coverage? Headlines about KZR stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Kezar Life Sciences' key competitors? Some companies that are related to Kezar Life Sciences include Prestige Consumer Healthcare (PBH), Innoviva (INVA), Endo International (ENDP), Cambrex (CBM), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Theravance Biopharma (TBPH) and Epizyme (EPZM). What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Gilead Sciences (GILD), Apollo Commercial Real Est. Finance (ARI), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Akorn (AKRX), Align Technology (ALGN), Amarin (AMRN), Ares Capital (ARCC), BIOLINERX LTD/S (BLRX) and Audentes Therapeutics (BOLD). Who are Kezar Life Sciences' key executives? Kezar Life Sciences' management team includes the folowing people: Mr. John Fowler, Co-Founder, CEO & Director (Age 47)Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)Dr. Jack Taunton, Co-FounderMr. Marc L. Belsky, CFO & Sec. (Age 64)Michael Wolfe, Director of Fin. & Operations When did Kezar Life Sciences IPO? (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO. Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.42%), BlackRock Inc. (3.32%), Victory Capital Management Inc. (1.17%), Slow Capital Inc. (1.08%), Northern Trust Corp (0.66%) and Marshall Wace LLP (0.21%). Company insiders that own Kezar Life Sciences stock include Franklin M Berger and Morningside Venture Investment. View Institutional Ownership Trends for Kezar Life Sciences. Which institutional investors are selling Kezar Life Sciences stock? KZR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley and Victory Capital Management Inc.. View Insider Buying and Selling for Kezar Life Sciences. Which institutional investors are buying Kezar Life Sciences stock? KZR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Slow Capital Inc., Northern Trust Corp, Marshall Wace LLP, Charles Schwab Investment Management Inc., Rhumbline Advisers, Spark Investment Management LLC and Ironsides Asset Advisors LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Franklin M Berger and Morningside Venture Investment. View Insider Buying and Selling for Kezar Life Sciences. How do I buy shares of Kezar Life Sciences? Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kezar Life Sciences' stock price today? One share of KZR stock can currently be purchased for approximately $20.09. How big of a company is Kezar Life Sciences? Kezar Life Sciences has a market capitalization of $384.12 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe. What is Kezar Life Sciences' official website? The official website for Kezar Life Sciences is http://www.kezarlifesciences.com. How can I contact Kezar Life Sciences? Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected] MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)Community Ranking: 1.9 out of 5 ()Outperform Votes: 49 (Vote Outperform)Underperform Votes: 77 (Vote Underperform)Total Votes: 126MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: The primary rules of Elliott Wave theory Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.